MDWD Stock Analysis: Buy, Sell, or Hold?
MDWD - MediWound Ltd.
$13.21
0.10 (0.72%)
▲
5d:
-2.58%
30d:
-7.43%
90d:
-21.56%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When MDWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MDWD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MDWD shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MDWD is currently trading at $13.21, which is considered oversold relative to its 30-day fair value range of $13.63 to $14.50.
Technical Outlook: Technically, MDWD is in a strong downtrend. The price is currently testing key support at $13.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MDWD scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $29.83 (+125.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MDWD is in a strong downtrend. The price is currently testing key support at $13.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MDWD scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $29.83 (+125.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.63 -
$14.50
Company Quality Score
40/100
(HOLD)
Options IV Signal
38th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 38th percentile)
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 125.8% below Wall St target ($29.83)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.63 -
$14.50
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.98
(15.0%)
Support & Resistance Levels
Support Level
$13.06
Resistance Level
$14.53
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.77
Wall Street Target
$29.83
(+125.8%)
Revenue Growth (YoY)
-45.8%
Profit Margin
-170.1%
Share & Embed Analysis
Last updated: August 24, 2026 8:30 AM ET
Data refreshes hourly during market hours. Next update: 9:30 AM
Data refreshes hourly during market hours. Next update: 9:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
